Assessing quantitative chimerism longitudinally: Technical considerations, clinical applications and routine feasibility

D. Kristt*, J. Stein, I. Yaniv, T. Klein

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


In this review, we describe the current laboratory approach to quantitative chimerism testing based on short tandem repeats (STRs), focusing on a longitudinal analysis. The latter is based on relative changes appearing in the course of sequential samples, and as such exploits the ultimate potential of this intrinsically semiquantitative platform. Such an analysis is more informative than single static values, less likely to be confused with platform artifacts, and is individualized to the particular patient. It is particularly useful with non-myeloablative conditioning, where mixed chimerism is common. Importantly, longitudinal monitoring is a routinely feasible laboratory option because multiplex STR-polymerase chain reaction kits are available commercially, and modern software can be used to perform computation, reliability testing and longitudinal tracking in a rapid, easy to use format. The ChimerTrack application, a shareware, user friendly program developed for this purpose, produces a report that automatically summarizes and illustrates the quantitative temporal course of the patient's chimeric status. Such a longitudinal perspective enhances the value of quantitative chimerism monitoring for decisions regarding immunomodulatory post transplant therapy. This information also provides unique insights into the biological dynamics of engraftment underlying the fluctuations in the temporal course of a patient's chimeric status.

Original languageEnglish
Pages (from-to)255-268
Number of pages14
JournalBone Marrow Transplantation
Issue number5
StatePublished - Mar 2007


FundersFunder number
Hirsh and Gania Wassermann
Tel Aviv University


    Dive into the research topics of 'Assessing quantitative chimerism longitudinally: Technical considerations, clinical applications and routine feasibility'. Together they form a unique fingerprint.

    Cite this